These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Erickson SC, Le L, Ramsey SD, Solow BK, Zakharyan A, Stockl KM, Harada AS, Curtis B. Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778 [Abstract] [Full Text] [Related]
5. The risks and costs of multiple-generic substitution of topiramate. Duh MS, Paradis PE, Latrémouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J. Neurology; 2009 Jun 16; 72(24):2122-9. PubMed ID: 19528520 [Abstract] [Full Text] [Related]
6. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. Paradis PE, Latrémouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS. Curr Med Res Opin; 2009 Jul 16; 25(7):1793-805. PubMed ID: 19505202 [Abstract] [Full Text] [Related]
7. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Makus KG, McCormick J. Clin Ther; 2007 Feb 16; 29(2):334-41. PubMed ID: 17472825 [Abstract] [Full Text] [Related]
8. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study. Hartung DM, Middleton L, Svoboda L, McGregor JC. CNS Drugs; 2012 Aug 01; 26(8):707-16. PubMed ID: 22731934 [Abstract] [Full Text] [Related]
9. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. LeLorier J, Duh MS, Paradis PE, Latrémouille-Viau D, Lefebvre P, Manjunath R, Sheehy O. Curr Med Res Opin; 2008 Apr 01; 24(4):1069-81. PubMed ID: 18315941 [Abstract] [Full Text] [Related]
11. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand. Lessing C, Ashton T, Davis P. Appl Health Econ Health Policy; 2014 Oct 01; 12(5):537-46. PubMed ID: 25005492 [Abstract] [Full Text] [Related]
14. Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands. Knoester PD, Belitser SV, Deckers CL, Keyser A, Renier WO, Egberts AC, Hekster YA. J Clin Pharm Ther; 2004 Apr 01; 29(2):131-8. PubMed ID: 15068401 [Abstract] [Full Text] [Related]
15. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy. Das S, Jiang X, Jiang W, Ting TY, Polli JE. Epilepsy Behav; 2020 Apr 01; 105():106936. PubMed ID: 32092462 [Abstract] [Full Text] [Related]
16. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. Contin M, Alberghini L, Candela C, Benini G, Riva R. Epilepsy Res; 2016 May 01; 122():79-83. PubMed ID: 26987080 [Abstract] [Full Text] [Related]
20. Association between switching antiepileptic drug products and healthcare utilization: A systematic review. Kwan P, Palmini A. Epilepsy Behav; 2017 Aug 01; 73():166-172. PubMed ID: 28641169 [Abstract] [Full Text] [Related] Page: [Next] [New Search]